Literature DB >> 24247994

Reversible vigabatrin-induced life-threatening encephalopathy.

Yaiza Hernández Vega1, Marios Kaliakatsos1, Jean-Marie U-King-Im2, Karine Lascelles1, Ming Lim1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24247994     DOI: 10.1001/jamaneurol.2013.1858

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  5 in total

1.  Vigabatrin-Induced Encephalopathy; Fidaxomicin Hypersensitivity Reactions; Vemurafenib-Induced DRESS; Severe Alkalosis and Hypokalemia With Stanozolol Misuse; Isotretinoin-Associated Lip Abscess; Eltrombopag-Associated Hyperpigmentation.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2014-05

Review 2.  Medical treatment of tuberous sclerosis-related epilepsy.

Authors:  Shimrit Uliel-Sibony; Veronika Chernuha; Hadas Meirson; Aviva Fattal-Valevski
Journal:  Childs Nerv Syst       Date:  2020-08-22       Impact factor: 1.475

Review 3.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

4.  Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies.

Authors:  Nathan L Absalom; Vivian W Y Liao; Kavitha Kothur; Dinesh C Indurthi; Bruce Bennetts; Christopher Troedson; Shekeeb S Mohammad; Sachin Gupta; Iain S McGregor; Michael T Bowen; Damien Lederer; Sandrine Mary; Liesbeth De Waele; Katrien Jansen; Deepak Gill; Manju A Kurian; Amy McTague; Rikke S Møller; Philip K Ahring; Russell C Dale; Mary Chebib
Journal:  Brain Commun       Date:  2020-10-01

5.  High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex.

Authors:  Shaun A Hussain; Ernst Schmid; Jurriaan M Peters; Monisha Goyal; E Martina Bebin; Hope Northrup; Mustafa Sahin; Darcy A Krueger; Joyce Y Wu
Journal:  Epilepsy Res       Date:  2018-10-02       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.